Table 2. The relationship between clinical parameters or pathologic characteristics and the frequency of PD-L1 reactivity before or after the starting of CIRT.
Variables | Total No. of patients | Pre-CIRT PD-L1 expression | p-value | Post-12Gy-C PD-L1 expression | p-value | |||
---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | |||||
No. of patients | 33 | 15 | 18 | 22 | 11 | |||
Age (yr) | 0.227 | 0.806 | ||||||
≤60 | 17 | 6 | 11 | 11 | 6 | |||
>60 | 16 | 9 | 7 | 11 | 5 | |||
Clinical stage | 0.135 | 0.314 | ||||||
≤IIB | 13 | 8 | 5 | 10 | 3 | |||
≥III | 20 | 7 | 13 | 12 | 8 | |||
Histological subclassification | 0.381 | 0.706 | ||||||
Adenocarcinoma | 29 | 14 | 15 | 19 | 10 | |||
Adenosquamous carcinoma | 4 | 1 | 3 | 3 | 1 | |||
Maximum tumor size (cm) | 0.898 | 1.000 | ||||||
≤5.3 | 18 | 8 | 10 | 12 | 6 | |||
>5.3 | 15 | 7 | 8 | 10 | 5 | |||
Lymph node metastasis | 0.515 | 0.801 | ||||||
Positive | 13 | 5 | 8 | 9 | 4 | |||
Negative | 20 | 10 | 10 | 13 | 7 |
CIRT, carbon-ion radiotherapy; PD-L1, programmed cell death-ligand 1.